Table 1. In vivo bioassay of the infectious properties of the novel tagged-PrP molecules generated in PrP-224AlaMYC cells.
| Inocula | SCA (PrPSc positive cells) | Incubation time (days) |
Analysis |
|
|---|---|---|---|---|
| Pathological | Biochemical | |||
| PrP-224AlaMYC cells | ||||
| +RML | 321 | 67±1.03* | 4/4 | 2/2 |
| Control | 24 | — | 0/2 | 0/4 |
| PK1 cells | ||||
| +RML | 1628 | 66±1.38 | 5/5 | 2/2 |
| PK1-10Si8 PrP-KD cells | ||||
| +RML |
15 |
— |
0/2 |
0/4 |
RML, Rocky Mountain Laboratory; SCA: scrapie cell assay.
SCA (the mean from six replicates is shown).
Standard histopathological analysis as shown in Figure 1e was performed on the indicated number of animals from each group—prion disease was confirmed by H&E, GFAP and PrPSc staining.
Biochemical analysis as shown in Figure 1d was performed on the indicated number of animals from each group—prion disease was confirmed by the detection of PK resistant PrP in brain homogenates.
*Mean±s.d., n⩾4.